Adiponectin is required for pioglitazone-induced improvements in hepatic steatosis in mice fed a high-fat diet

Autor(es)

de Mendonca, Mariana ^[1] ; Cardoso dos Santos, Bruna de Araujo ^[1] ; de Sousa, Erica ^[1] ; Rodrigues, Alice Cristina ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Dept Pharmacol, Inst Biomed Sci, Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Molecular and Cellular Endocrinology; v. 493, AUG 1 2019.
• Citações Web of Science: 1

Resumo

Pioglitazone has been used for the treatment of nonalcoholic fatty liver disease (NAFLD) related to diabetes. The role of adiponectin in pioglitazone-induced improvements in NAFLD was studied by using wild-type (adipoWT) and adiponectin knockout (adipoKO) mice. High-fat diet fed mice were insulin resistant, glucose intolerant and had increased hepatic lipid accumulation as evidenced by increased NAFLD activity score. Despite pioglitazone has improved insulin resistance in both genotypes, hepatic steatosis was only improved in adipoWT obese mice. Amelioration of NAFLD in adipoWT mice promoted by pioglitazone was associated with up-regulation of Pparg, Fgf21 and down-regulation of Pepck liver expression. On the other hand, resistance to pioglitazone treatment in adipoKO mice was associated with increased expression of miR-192 and Hsl, which was not followed by increased fatty acid oxidation. In conclusion, our data provides evidence that increased adiponectin production by pioglitazone is necessary for its beneficial action on NAFLD. (AU)

• Processo FAPESP: 15/24650-0 - Papel do microRNAs no controle da expressão gênica de adiponectina
• Beneficiário: Mariana de Mendonça
• Linha de fomento: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 15/24789-8 - MicroRNAs na via de sinalização de adiponectina: possíveis alvos terapêuticos na melhora da resistência à insulina e de doenças associadas.
• Beneficiário: Alice Cristina Rodrigues
• Linha de fomento: Auxílio à Pesquisa - Regular